Monte Rosa Therapeutics Inc (GLUE)

May 05, 2025

Monte Rosa Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

May 05, 2025

May 04, 2025

Wells Fargo & Company MN Buys 47,952 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

May 04, 2025

Apr 28, 2025

Monte Rosa reports breakthrough in breast cancer treatment - Investing.com Australia

Apr 28, 2025

Apr 28, 2025

Monte Rosa reports breakthrough in breast cancer treatment By Investing.com - Investing.com South Africa

Apr 28, 2025

Apr 28, 2025

Monte Rosa Therapeutics (GLUE) to Unveil Promising Breast Cancer Data at AACR 2025 | GLUE Stock News - GuruFocus

Apr 28, 2025

Apr 28, 2025

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewswire

Apr 28, 2025

Apr 28, 2025

Breakthrough: New Molecular Glue Degrader Achieves 77% Tumor Shrinkage in Hard-to-Treat Breast Cancer - Stock Titan

Apr 28, 2025

Apr 26, 2025

Monte Rosa Therapeutics Inc (GLUE) Sits And Waits For Direction At $5.06 Price - Stocksregister

Apr 26, 2025

Apr 25, 2025

Geode Capital Management LLC Lowers Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 25, 2025

Apr 24, 2025

Can you now get a good deal on Monte Rosa Therapeutics Inc’s shares? - uspostnews.com

Apr 24, 2025

Apr 24, 2025

Market Watch Highlights: Monte Rosa Therapeutics Inc (GLUE) Ends on an Upturn Note at 5.33 - DWinneX

Apr 24, 2025

Apr 24, 2025

GLUE’s 2023 Market Dance: Down -23.20% – Time to Invest? - investchronicle.com

Apr 24, 2025

Apr 22, 2025

How To Trade (GLUE) - news.stocktradersdaily.com

Apr 22, 2025

Apr 22, 2025

Monte Rosa Therapeutics Insider Ups Holding During Year - Yahoo Finance

Apr 22, 2025

Apr 20, 2025

Franklin Resources Inc. Buys Shares of 27,510 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 20, 2025

Apr 16, 2025

Vanguard Group Inc. Buys 622,134 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 16, 2025

Apr 14, 2025

Wellington Management Group LLP Grows Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 14, 2025

Apr 13, 2025

American Century Companies Inc. Has $533,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 13, 2025

Apr 12, 2025

Sei Investments Co. Buys Shares of 17,236 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Apr 12, 2025

Apr 06, 2025

How to Take Advantage of moves in (GLUE) - news.stocktradersdaily.com

Apr 06, 2025

Mar 29, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Holdings Boosted by Charles Schwab Investment Management Inc. - Defense World

Mar 29, 2025

Mar 27, 2025

Chandra Leo Spends US$58k On Monte Rosa Therapeutics Stock - simplywall.st

Mar 27, 2025

Mar 26, 2025

Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock By Investing.com - Investing.com India

Mar 26, 2025

Mar 25, 2025

Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock - Investing.com

Mar 25, 2025

Mar 25, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Position Lifted by Bank of New York Mellon Corp - Defense World

Mar 25, 2025

Mar 25, 2025

What is Wedbush’s Forecast for GLUE FY2029 Earnings? - The AM Reporter

Mar 25, 2025

Mar 24, 2025

Monte Rosa Therapeutics: Exercise Extreme Caution (NASDAQ:GLUE) - Seeking Alpha

Mar 24, 2025

Mar 24, 2025

FY2029 Earnings Estimate for GLUE Issued By Wedbush - Defense World

Mar 24, 2025

Mar 23, 2025

Wells Fargo & Company Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - Defense World

Mar 23, 2025

Mar 22, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025

Mar 22, 2025

Wedbush Reaffirms Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World

Mar 22, 2025

Mar 22, 2025

Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics - TipRanks

Mar 22, 2025

Mar 22, 2025

Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN

Mar 22, 2025

Mar 21, 2025

Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts - TipRanks

Mar 21, 2025

Mar 21, 2025

Positive signs for Monte Rosa in early data - The Pharma Letter

Mar 21, 2025

Mar 20, 2025

Monte Rosa Therapeutics Reports Strong Q4 2024 Results - TipRanks

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs - TipRanks

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics shares surge on strong Q4 revenue beat - Investing.com

Mar 20, 2025

Mar 20, 2025

Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Benzinga

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics earnings missed by $0.54, revenue topped estimates - Investing.com Canada

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics shares surge on strong Q4 revenue beat By Investing.com - Investing.com Australia

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Mar 20, 2025

Mar 20, 2025

Monte Rosa Therapeutics Files $400 Million Mixed Shelf - MarketScreener

Mar 20, 2025

Mar 20, 2025

Earnings call transcript: Monte Rosa Therapeutics Q4 2024 shows strong cash runway - Investing.com

Mar 20, 2025

Mar 20, 2025

MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq

Mar 20, 2025